OA12431A - Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. - Google Patents

Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. Download PDF

Info

Publication number
OA12431A
OA12431A OA1200300119A OA1200300119A OA12431A OA 12431 A OA12431 A OA 12431A OA 1200300119 A OA1200300119 A OA 1200300119A OA 1200300119 A OA1200300119 A OA 1200300119A OA 12431 A OA12431 A OA 12431A
Authority
OA
OAPI
Prior art keywords
oxidized
médicament
proteins
binding
protein
Prior art date
Application number
OA1200300119A
Other languages
English (en)
Inventor
Beate Kehrel
Martin Brodde
Original Assignee
Beate Kehrel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/de
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/de
Application filed by Beate Kehrel filed Critical Beate Kehrel
Publication of OA12431A publication Critical patent/OA12431A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
OA1200300119A 2000-10-20 2001-10-19 Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. OA12431A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (de) 2000-10-20 2000-10-20 Inhibierung der pathogenen Wirkung oxidierter Proteine
DE2001148624 DE10148624A1 (de) 2001-10-02 2001-10-02 Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten

Publications (1)

Publication Number Publication Date
OA12431A true OA12431A (en) 2006-04-19

Family

ID=26007431

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300119A OA12431A (en) 2000-10-20 2001-10-19 Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Country Status (13)

Country Link
EP (2) EP1994941A3 (fr)
JP (1) JP4881535B2 (fr)
AP (2) AP2781A (fr)
AT (1) ATE406908T1 (fr)
AU (1) AU2002215032A1 (fr)
CA (1) CA2453140C (fr)
CY (1) CY1110418T1 (fr)
DE (1) DE50114289D1 (fr)
DK (1) DK1328289T3 (fr)
ES (1) ES2307662T3 (fr)
OA (1) OA12431A (fr)
PT (1) PT1328289E (fr)
WO (1) WO2002032445A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079440A1 (en) * 2003-04-25 2006-04-13 Kehrel Beate E Treatment of hi-virus infections with oxidised blood proteins
CA2947330C (fr) 2005-09-16 2018-06-05 Cornell Research Foundation, Inc. Methodes permettant de reduire l'expression de cd36
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
DE102011003936A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
WO2013082458A1 (fr) 2011-12-02 2013-06-06 The Regents Of The University Of California Solution de protection de reperfusion et ses utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
JPH05500963A (ja) * 1989-10-06 1993-02-25 ザ　ベス　イスラエル　ホスピタル　アソシエイション 新規な酸化脂肪蛋白質とその調合方法
WO1991010684A1 (fr) * 1990-01-08 1991-07-25 Schering Corporation Variantes oxydees de gm-csf
JPH05508159A (ja) * 1990-07-18 1993-11-18 ザ　ベス　イスラエル　ホスピタル　アソシエイション 酸化リポプロテインを使用するウイルス感染症の治療方法
WO1995013096A1 (fr) 1993-11-08 1995-05-18 Peptide Delivery Systems Pty. Ltd. Compositions de diagnostic marquees et leurs procedes d'utilisation
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
CA2294355C (fr) 1997-06-20 2006-11-28 Leuven Research & Development Vzw Dosages, anticorps et etalons de detection de lipoproteines de basse densite, oxydees et modifiees par mda
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
CA2348685A1 (fr) * 1998-11-06 2000-05-18 Emory University Biomarqueurs du stress d'oxydation
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III

Also Published As

Publication number Publication date
JP2004511526A (ja) 2004-04-15
EP1328289A2 (fr) 2003-07-23
CA2453140C (fr) 2016-01-05
JP4881535B2 (ja) 2012-02-22
EP1328289B1 (fr) 2008-09-03
CA2453140A1 (fr) 2002-04-25
DK1328289T3 (da) 2008-12-15
AU2002215032A1 (en) 2002-04-29
AP2781A (en) 2013-10-31
CY1110418T1 (el) 2015-04-29
HK1057857A1 (en) 2004-04-23
ATE406908T1 (de) 2008-09-15
AP2034A (en) 2009-08-28
WO2002032445A2 (fr) 2002-04-25
AP2009004857A0 (en) 2009-06-30
EP1994941A2 (fr) 2008-11-26
PT1328289E (pt) 2008-12-10
ES2307662T3 (es) 2008-12-01
WO2002032445A3 (fr) 2003-04-17
AP2003002795A0 (en) 2003-06-30
DE50114289D1 (de) 2008-10-16
EP1994941A3 (fr) 2012-07-25

Similar Documents

Publication Publication Date Title
CN1254275C (zh) 抗血栓药剂和抗维勒布兰德因子单克隆抗体
HUP0200353A2 (hu) Fehérje, vérlemezkék tapadásának gátlására
US7273925B1 (en) Methods and products for regulating lectin complement pathway associated complement activation
Lima et al. From patients to platelets and back again: pharmacological approaches to glycoprotein VI, a thrilling antithrombotic target with minor bleeding risks
WO2000035483A1 (fr) Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine
PL204449B1 (pl) DNA kodujący glikoproteinę VI
US8034769B2 (en) Oxidized proteins and oxidized protein inhibitor compositions and methods of use thereof
CA2453140C (fr) Proteines oxydees, leur activite biologique et mesures therapeutiques et diagnostiques, qui sont derivees du mecanisme actif, a partir de l'utilisation de ces proteines et a partir de l'inhibition de celles-ci
KR20010102130A (ko) 지혈 및 면역기능에 사용하기 위한 억제제
US20110236455A1 (en) Novel Regulators of the Innate Immune System
WO2007011682A2 (fr) Procedes et reactifs pour cribler de nouveaux medicaments et pour traiter des troubles et maladies associes a la pompe ionique
JP2006516024A (ja) α１β１インテグリンの誘導性リガンドおよび使用
US20030022350A1 (en) Antithrombosis enzyme from the snake venom of Agkistrodon acutus
DE10148624A1 (de) Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten
WO2016021894A1 (fr) Composition pharmaceutique pour prévenir ou traiter une sénescence cellulaire ou des maladies associées à la sénescence, contenant un anticorps cd9 comme principe actif
HK1057857B (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
O'Sullivan An investigation of the role of ACTN1 in platelet formation and of platelet function in myeloma
HK1121392A (en) Medicine containing at least one oxidised protein
CN110272477A (zh) 与内皮细胞激活相关的靶点comp及其应用
Visconte Roles of Amyloid Precursor Protein in Platelet Function
Szewczyk BIOTECHNOLOGICAL INVENTION OF CALOXINS-A NOVEL CLASS OF ALLOSTERIC INHIBITORS SPECIFIC FOR PLASMA MEMBRANE CALCIUM PUMP ISOFORMS
Ye The role of syntaxin and tomosyn in platelet secretion
RA Impaired platelet function in a patient with P2Y, deficiency caused by a mutation in the translation initiation codon
EP2789631A1 (fr) Composés et procédés pour l'inhibition de liaison ICAM-4 vers de l'intégrine plaquettaire alphaIibbeta3
FR2895262A1 (fr) Inhibition de la reponse immunitaire anti-fviii